ProCE Banner Activity

Phase II GEM-CESAR: KRd + ASCT in High-Risk Smoldering Myeloma

Slideset Download
Conference Coverage
The use of KRd induction plus transplantation and consolidation resulted in a CR or better in approximately 75% of patients with high-risk smoldering myeloma with an acceptable safety profile.

Released: December 12, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology